Skip to main content

Advertisement

SpringerLink
Log in

Aspirin Use and Transcatheter Pulmonary Valve Replacement, the Need for Consistency

  • Original Article
  • Published:
Pediatric Cardiology Aims and scope Submit manuscript

Abstract

Transcatheter pulmonary valve replacement (TPVR) is a staple in the pediatric cardiac catheterization lab. Despite the ubiquitous use of this procedure, guidelines for antithrombosis post pulmonary valve replacement are non-existent. A survey was sent out via email to the members of the Congenital Cardiovascular Interventional Study Consortium (CCISC) and the Pediatric and Adult Interventional Cardiac Symposium (PICS-AICS). Responses were received from 109 cardiologists who perform this procedure. Following TPVR 76.5% of respondents use only Aspirin, while the remainder prescribe a second antithrombotic agent at discharge. The majority (78%) of respondents do not educate patients about avoiding enteric formulations of aspirin, and another 86% do not educate patients about the need to avoid proton pump inhibitors (PPI). In addition, 67% do not advise against concomitant use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Lastly, the survey showed a wide discrepancy in prescribed dose with 56% choosing to always prescribe 70–100 mg regardless of weight, 28% choosing to do weight-based dosing, and 7.5% choosing 325 mg regardless of weight. In a survey sent out to pediatric cardiac interventionalists worldwide, a significant discrepancy was noted in antithrombotic regimens used following TPVR. We hypothesize that these discrepancies may contribute to early valve failure and suggest the need for further study and the development of unified antithrombosis guidelines following TPVR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Georgiev S, Ewert P, Tanase D, Hess J, Hager A, Cleuziou J, Meierhofer C, Eicken A (2019) A low residual pressure gradient yields excellent long-term outcome after percutaneous pulmonary valve implantation. JACC Cardiovasc Interv 12:1594–1603

    Article  Google Scholar 

  2. Haas NA, Carere RG, Kretschmar O, Horlick E, Rodes-Cabau J, de Wolf D, Gewillig M, Mullen M, Lehner A, Deutsch C, Bramlage P, Ewert P (2018) Early outcomes of percutaneous pulmonary valve implantation using the Edwards SAPIEN XT transcatheter heart valve system. Int J Cardiol 250:86–91

    Article  Google Scholar 

  3. Kenny D, Hijazi ZM, Kar S, Rhodes J, Mullen M, Makkar R, Shirali G, Fogel M, Fahey J, Heitschmidt MG, Cain C (2011) Percutaneous implantation of the Edwards SAPIEN transcatheter heart valve for conduit failure in the pulmonary position: early phase 1 results from an international multicenter clinical trial. J Am Coll Cardiol 58:2248–2256

    Article  Google Scholar 

  4. Ghawi H, Kenny D, Hijazi ZM (2012) Transcatheter pulmonary valve replacement. Cardiol Ther 1:5

    Article  Google Scholar 

  5. Cabalka AK, Hellenbrand WE, Eicken A, Kreutzer J, Gray RG, Bergersen L, Berger F, Armstrong AK, Cheatham JP, Zahn EM, McElhinney DB (2017) Relationships among conduit type, pre-stenting, and outcomes in patients undergoing transcatheter pulmonary valve replacement in the prospective North American and European Melody Valve Trials. JACC Cardiovasc Interv 10:1746–1759

    Article  Google Scholar 

  6. Malekzadeh-Milania S, Ladouceura M, Patel M, Boughenoua FM, Iserin L, Bonne D, Boudjemline Y (2015) Incidence and predictors of Melody® valve endocarditis: a prospective study. Arch Cardiovasc Dis 108:97–106

    Article  Google Scholar 

  7. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O’Gara PT, Rigolin VH, Sundt TM 3rd, Thompson A, Toly C (2020) 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. https://doi.org/10.1161/CIR.0000000000000923

    Article  PubMed  Google Scholar 

  8. Cipollone F, Patrignani P, Greco A, Rosaria Panara M, Padovano R, Cuccurullo F, Patrono C, Rebuzzi AG, Liuzzo G, Quaranta G, Maseri A (1997) Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 96:1109–1116

    Article  CAS  Google Scholar 

  9. Antman EMAD, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. Circulation 110:588–636

    Article  Google Scholar 

  10. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI (2012) Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e89S-e119S

    Article  CAS  Google Scholar 

  11. Wurtz M, Grove EL, Kristensen SD, Hvas AM (2010) The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart 96:368–371

    Article  CAS  Google Scholar 

  12. Warner TD, Nylander S, Whatling C (2011) Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol 72:619–633

    Article  CAS  Google Scholar 

  13. Campbell CL, Steinhubl SR (2005) Variability in response to aspirin—do we understand the clinical relevance. J Thromb Hemost 3:5

    Article  Google Scholar 

  14. Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP, Montalescot G, Macaya C, Pasquale GD, Niemela K, Ajani AE, White HD, Chrolavicius S, Gao P, Fox KAA, YusuF S (2010) Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. The Lancet 376:10

    Article  Google Scholar 

  15. Rosseel L, De Backer O, Sondergaard L (2019) Clinical valve thrombosis and subclinical leaflet thrombosis following transcatheter aortic valve replacement: is there a need for a patient-tailored antithrombotic therapy? Front Cardiovasc Med 6:44

    Article  Google Scholar 

  16. Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US (2007) Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 115:3156–3164

    Article  CAS  Google Scholar 

  17. Dawson J, Quinn T, Rafferty M, Higgins P, Ray G, Lees KR, Walters MR (2011) Aspirin resistance and compliance with therapy. Cardiovasc Ther 29:301–307

    Article  CAS  Google Scholar 

  18. Shantsila E, Lip GY (2008) “Aspirin resistance” or treatment non-compliance: which is to blame for cardiovascular complications? J Transl Med 6:47

    Article  Google Scholar 

  19. Schwartz KA, Schwartz DE, Barber K, Reeves M, De Franco AC (2008) Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J Transl Med 6:46

    Article  Google Scholar 

Download references

Funding

No funding was required for this manuscript.

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Pediatrics, University of Iowa Stead Family Children’s Hospital, Iowa City, IA, USA

    Kamel Shibbani

  2. Department of Pediatrics and Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA

    Ruchira Garg & Evan M. Zahn

  3. Division of Cardiology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA

    Daniel Mclennan

Authors
  1. Kamel Shibbani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ruchira Garg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Evan M. Zahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniel Mclennan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed equally to this work.

Corresponding author

Correspondence to Daniel Mclennan.

Ethics declarations

Conflict of interest

Evan Zahn is a proctor, a consultant and a former site Principle Investigator for Medtronic. Evan Zahn is a proctor, a consultant, and a national Principle Investigator for Edwards.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shibbani, K., Garg, R., Zahn, E.M. et al. Aspirin Use and Transcatheter Pulmonary Valve Replacement, the Need for Consistency. Pediatr Cardiol 42, 1640–1646 (2021). https://doi.org/10.1007/s00246-021-02652-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00246-021-02652-8

Keywords

Search

Navigation